Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2014; 20(38): 13973-13980
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13973
Simultaneous modulated accelerated radiation therapy for esophageal cancer: A feasibility study
Wu-Zhe Zhang, Jian-Zhou Chen, De-Rui Li, Zhi-Jian Chen, Hong Guo, Ting-Ting Zhuang, Dong-Sheng Li, Ming-Zhen Zhou, Chuang-Zhen Chen
Wu-Zhe Zhang, Jian-Zhou Chen, De-Rui Li, Zhi-Jian Chen, Hong Guo, Ting-Ting Zhuang, Dong-Sheng Li, Ming-Zhen Zhou, Chuang-Zhen Chen, Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, Guangdong Province, China
Author contributions: Zhang WZ and Chen JZ contributed equally to this work; Li DR, Chen ZJ and Chen CZ designed the research; Zhang WZ, Chen JZ, Guo H, and Zhuang TT performed the research; Li DS and Zhou MZ analyzed the data; Chen JZ and Chen CZ wrote the paper.
Supported by Shantou University Medical College Clinical Research Enhancement Initiative, and Research and Travel Grants from the Science and Technology Key Project of Shantou City, China, 2012, No. 2012-165-131
Correspondence to: Chuang-Zhen Chen, MD, Department of Radiation Oncology, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou 515031, Guangdong Province, China. stccz@139.com
Telephone: +86-754-88555844-1086 Fax: +86-754-88560352
Received: February 27, 2014
Revised: June 4, 2014
Accepted: June 25, 2014
Published online: October 14, 2014
Processing time: 230 Days and 16.1 Hours
Core Tip

Core tip: The feasibility of simultaneous modulated accelerated radiotherapy (SMART) in the treatment of upper or middle thoracic esophageal cancer is evaluated in this study. Computed tomography datasets of 10 patients were used to generate SMART, conventionally-fractionated three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (cf-IMRT) plans, respectively. The prescribed dose for the SMART plans was 66 Gy/30 F to the gross tumor and 54 Gy/30 F to subclinical diseases. The dose for both the 3DCRT and cf-IMRT was 60 Gy/30 F to a single target volume. The results demonstrate that SMART can offer the potential for a 6 Gy simultaneous escalation in the dose delivered to the primary tumor of esophageal cancer and improve normal tissue sparing compared with 3DCRT and cf-IMRT.